ASP-2138

DB18473Investigational

ASP-2138 is a bispecific antibody directed against CLDN18.2 and T cell receptor complex CD3.

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 and Claudin-18
Curator reviewed
Code names: ASP-2138

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with ASP-2138, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.